Phosphate diabetes

Common Name(s)

Phosphate diabetes

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Phosphate diabetes" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Phosphate diabetes" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Phosphate diabetes" returned 28 free, full-text research articles on human participants. First 3 results:

The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
 

Author(s): Feryal Al-Saber, Waleed Aldosari, Mariam Alselaiti, Hesham Khalfan, Ahmed Kaladari, Ghulam Khan, George Harb, Riyadh Rehani, Sizuka Kudo, Aya Koda, Tohru Tanaka, Motowo Nakajima, Abdulla Darwish

Journal: J Diabetes Res. 2016 ;2016():8294805.

 

Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients. A multifaceted treatment approach can include nutritional supplements with antioxidant properties such as 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC). ...

Last Updated: 14 Oct 2016

Go To URL
Tumor Necrosis Factor/Sphingosine-1-Phosphate Signaling Augments Resistance Artery Myogenic Tone in Diabetes.
 

Author(s): Meghan Sauvé, Sonya K Hui, Danny D Dinh, Warren D Foltz, Abdul Momen, Sergei A Nedospasov, Stefan Offermanns, Mansoor Husain, Jeffrey T Kroetsch, Darcy Lidington, Steffen-Sebastian Bolz

Journal: Diabetes. 2016 Jul;65(7):1916-28.

 

Diabetes strongly associates with microvascular complications that ultimately promote multiorgan failure. Altered myogenic responsiveness compromises tissue perfusion, aggravates hypertension, and sets the stage for later permanent structural changes to the microcirculation. We demonstrate ...

Last Updated: 22 Jun 2016

Go To URL
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection.
 

Author(s): Jonas W Brinck, Aurélien Thomas, Estelle Lauer, François R Jornayvaz, Marie-Claude Brulhart-Meynet, Jean-Christophe Prost, Zoltan Pataky, Patrik Löfgren, Johan Hoffstedt, Mats Eriksson, Camilla Pramfalk, Sandrine Morel, Brenda R Kwak, Miranda van Eck, Richard W James, Miguel A Frias

Journal: Arterioscler. Thromb. Vasc. Biol.. 2016 May;36(5):817-24.

 

The dyslipidemia of type 2 diabetes mellitus has multiple etiologies and impairs lipoprotein functionality, thereby increasing risk for cardiovascular disease. High-density lipoproteins (HDLs) have several beneficial effects, notably protecting the heart from myocardial ischemia. ...

Last Updated: 28 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Phosphate diabetes" returned 1 free, full-text review articles on human participants. First 3 results:

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
 

Author(s): Baptist Gallwitz

Journal: Vasc Health Risk Manag. 2007 ;3(2):203-10.

 

Sitagliptin (Januvia, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 ...

Last Updated: 21 Jun 2007

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
 

Status: Recruiting

Condition Summary: Diabetes; PTH; Vitamin D; Fibroblast Growth Factor (FGF23); Phosphate

 

Last Updated: 31 May 2017

Go to URL
Treatment of Diabetes in Patients With Systolic Heart Failure
 

Status: Recruiting

Condition Summary: Heart Failure, Systolic; Diabetes Mellitus, Type 2

 

Last Updated: 10 Nov 2016

Go to URL